Additionally, the trial showed no difference in median OS in the entire population, regardless of PD-L1 and histology (7.1 versus 7.1 months, HR: 0.89, p = 0.056) as well as no benefit in terms of median PFS (PD-L1 ≥ 10 subgroup: 2.6 versus 3.0 months in the experimental and control arm, respectively; ESCC subgroup: 2.2 versus 3.1 months; entire population: 2.1 versus 3.4 months). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.